COVID-19 Neutralising Antibody Testing 

The SARS-CoV-2 Neutralising Test (a.k.a Surrogate Virus Neutralization Antibody Detection) can evaluate the Covid-19 vaccine efficacy. This is a highly specific test that detects antibodies, which block the interaction between Spike-RBD domain of the virus and the ACE2 receptor on the human cell. Blocking that interaction can prevent the virus from entering and infecting the cells.

Infection with SARS-CoV-2 initiates an immune response, which includes the production of antibodies, or binding antibodies, in the blood. Not all binding antibodies can block cellular infiltration and replication of the SARS-CoV-2 virus. The subpopulation of the binding antibodies that can block cellular infiltration and replication of the virus are named neutralizing antibodies. While individuals infected with SARS-CoV-2 develop binding antibodies to the virus, not all of them develop neutralizing antibodies to SARS-CoV-2.